Skip to main content

Table 2 The assessment of the risk of bias in each cohort study using the Newcastle–Ottawa scale

From: Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis

Study

Selection (0–4)

Comparability (0–2)

Outcome (0–3)

Total

REC

SNEC

AE

DO

SC

AF

AO

FU

AFU

Ladoire S et al. [26]

1

1

1

1

0

0

1

0

0

5

Lee S et al. [30]

0

1

1

0

0

0

1

1

0

4

Mahmoud SMA et al. [27]

1

1

1

1

0

0

1

1

0

6

Liu F et al. [7]

1

1

1

1

1

0

1

1

0

7

West NR et al. [32]

1

1

1

1

0

0

1

1

0

6

Bates GJ et al. [23]

1

1

1

1

0

0

1

1

0

6

Takenaka M et al. [31]

1

1

1

1

0

0

1

1

0

6

Maeda N et al. [35]

1

1

1

1

0

0

1

1

0

6

Sun S et al. [36]

1

1

1

1

1

0

1

1

1

8

Aruga T et al. [24]

1

1

1

1

0

0

0

1

0

5

De Kruijf EM et al. [25]

1

1

1

1

1

0

1

1

0

7

Liu F et al. [28]

1

1

1

1

0

0

1

1

0

6

Liu S et al. [34]

1

1

1

1

0

0

1

1

0

6

Kim ST et al. [29]

0

1

1

1

0

0

0

0

0

3

Tsang JY et al. [37]

1

1

1

1

0

0

0

0

0

4

Kim S et al. [33]

1

1

1

1

0

0

0

1

0

5

Seo AN et al. [38]

1

1

1

1

0

0

0

0

0

4

  1. REC representativeness of the exposed cohort; SNEC selection of the non exposed cohort; AE ascertainment of exposure; DO demonstration that outcome of interest was not present at start of study; SC study controls for age, sex; AF study controls for any additional factor; AO assessment of outcome; FU follow-up long enough for outcomes to occur (36 Months); AFU Adequacy of follow up of cohorts (≥90 %).“1” means that the study is meeted the item and “0” means the opposite situation